Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
11 studies found for:    "microbicide" AND "gel" | Open Studies | HIV
Show Display Options
Rank Status Study
1 Recruiting Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use
Condition: HIV
Interventions: Drug: PC-1005;   Drug: HEC gel
2 Recruiting Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services
Condition: HIV
Intervention: Drug: 1% tenofovir gel
3 Unknown  An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots
Condition: HIV Infections
Intervention: Drug: HEC placebo gel
4 Not yet recruiting Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel
Condition: HIV Prevention
Interventions: Drug: Once Daily Application of TFV RG 1% Gel;   Drug: Once Daily Application of TFV RG 1% gel - Rectal;   Drug: Once Daily Application of TFV RG 1% gel - Rectal;   Drug: Once Daily Application of TFV RG 1% Gel - Vaginal
5 Recruiting Assessing the Safety of Dapivirine Gel and Film Formulations
Condition: HIV Infections
Interventions: Drug: Dapivirine Vaginal Film;   Drug: Dapivirine Vaginal Gel
6 Not yet recruiting Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women
Condition: HIV Infections
Interventions: Drug: 1% tenofovir gel;   Drug: Placebo gel
7 Not yet recruiting Comparison of Tenofovir Vaginal Gel and Film Formulations
Conditions: Healthy;   HIV
Interventions: Drug: Tenofovir Gel;   Drug: Tenofovir Film
8 Not yet recruiting Safety and Acceptability of Tenofovir 1% Gel in Adolescent Females
Condition: HIV Prevention
Interventions: Drug: TFV 1% vaginal gel;   Drug: HEC Placebo Gel
9 Recruiting A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04
Condition: HIV
Interventions: Drug: 1% vaginally applied tenofovir gel;   Drug: Tenofovir film- 10mg;   Drug: Tenofovir Film-40 mg
10 Recruiting Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Condition: HIV
Interventions: Drug: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet);   Drug: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel);   Drug: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
11 Unknown  Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra
Conditions: Children With Confirmed HIV Infection;   Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose;   Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
Intervention: Drug: Mycobutin

Indicates status has not been verified in more than two years